A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients

Mina Maftouh, Amir Avan, Niccola Funel, Elisa Paolicchi, Enrico Vasile, Paola Pacetti, Vanja Vaccaro, Pinuccia Faviana, Daniela Campani, Sara Caponi, Andrea Mambrini, Ugo Boggi, Maurizio Cantore, Michele Milella, Godefridus J. Peters, Michele Reni, Elisa Giovannetti

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim: EZH2 expression is a prognostic marker in radically resected pancreatic ductal adenocarcinoma (PDAC) patients. Here we investigated its role in locally advanced/metastatic patients, as well as candidate polymorphisms. Materials & methods: EZH2 expression and polymorphisms were evaluated by quantitative reverse transcription PCR in 32 laser microdissected tumors, while polymorphisms were also studied in blood samples from two additional cohorts treated with gemcitabine monotherapy (n = 93) or polychemotherapeutic regimens (n = 247). Results: EZH2 expression correlated with survival and with the rs6958683 polymorphism in the first cohort of patients, but this polymorphism was not associated with survival in our larger cohorts. Conclusion: EZH2 is a prognostic factor for locally advanced/metastatic PDACs, while candidate polymorphisms cannot predict clinical outcome. Other factors involved in EZH2 regulation, such as miR-101, should be investigated in accessible samples in order to improve the clinical management of advanced PDAC. Original submitted 31 July 2013; Revision submitted 4 November 201.

Original languageEnglish
Pages (from-to)609-618
Number of pages10
JournalPharmacogenomics
Volume15
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Pancreatic Neoplasms
gemcitabine
Adenocarcinoma
Survival
Reverse Transcription
Lasers
Polymerase Chain Reaction
Neoplasms

Keywords

  • EZH2
  • gemcitabine-based chemotherapy
  • locally advanced/metastatic
  • outcome
  • pancreatic ductal adenocarcinoma
  • SNP

ASJC Scopus subject areas

  • Pharmacology
  • Genetics
  • Molecular Medicine
  • Medicine(all)

Cite this

Maftouh, M., Avan, A., Funel, N., Paolicchi, E., Vasile, E., Pacetti, P., ... Giovannetti, E. (2014). A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. Pharmacogenomics, 15(5), 609-618. https://doi.org/10.2217/pgs.13.225

A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. / Maftouh, Mina; Avan, Amir; Funel, Niccola; Paolicchi, Elisa; Vasile, Enrico; Pacetti, Paola; Vaccaro, Vanja; Faviana, Pinuccia; Campani, Daniela; Caponi, Sara; Mambrini, Andrea; Boggi, Ugo; Cantore, Maurizio; Milella, Michele; Peters, Godefridus J.; Reni, Michele; Giovannetti, Elisa.

In: Pharmacogenomics, Vol. 15, No. 5, 2014, p. 609-618.

Research output: Contribution to journalArticle

Maftouh, M, Avan, A, Funel, N, Paolicchi, E, Vasile, E, Pacetti, P, Vaccaro, V, Faviana, P, Campani, D, Caponi, S, Mambrini, A, Boggi, U, Cantore, M, Milella, M, Peters, GJ, Reni, M & Giovannetti, E 2014, 'A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients', Pharmacogenomics, vol. 15, no. 5, pp. 609-618. https://doi.org/10.2217/pgs.13.225
Maftouh, Mina ; Avan, Amir ; Funel, Niccola ; Paolicchi, Elisa ; Vasile, Enrico ; Pacetti, Paola ; Vaccaro, Vanja ; Faviana, Pinuccia ; Campani, Daniela ; Caponi, Sara ; Mambrini, Andrea ; Boggi, Ugo ; Cantore, Maurizio ; Milella, Michele ; Peters, Godefridus J. ; Reni, Michele ; Giovannetti, Elisa. / A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. In: Pharmacogenomics. 2014 ; Vol. 15, No. 5. pp. 609-618.
@article{0d5c604e0c13449a912ec0431ea8c0c2,
title = "A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients",
abstract = "Aim: EZH2 expression is a prognostic marker in radically resected pancreatic ductal adenocarcinoma (PDAC) patients. Here we investigated its role in locally advanced/metastatic patients, as well as candidate polymorphisms. Materials & methods: EZH2 expression and polymorphisms were evaluated by quantitative reverse transcription PCR in 32 laser microdissected tumors, while polymorphisms were also studied in blood samples from two additional cohorts treated with gemcitabine monotherapy (n = 93) or polychemotherapeutic regimens (n = 247). Results: EZH2 expression correlated with survival and with the rs6958683 polymorphism in the first cohort of patients, but this polymorphism was not associated with survival in our larger cohorts. Conclusion: EZH2 is a prognostic factor for locally advanced/metastatic PDACs, while candidate polymorphisms cannot predict clinical outcome. Other factors involved in EZH2 regulation, such as miR-101, should be investigated in accessible samples in order to improve the clinical management of advanced PDAC. Original submitted 31 July 2013; Revision submitted 4 November 201.",
keywords = "EZH2, gemcitabine-based chemotherapy, locally advanced/metastatic, outcome, pancreatic ductal adenocarcinoma, SNP",
author = "Mina Maftouh and Amir Avan and Niccola Funel and Elisa Paolicchi and Enrico Vasile and Paola Pacetti and Vanja Vaccaro and Pinuccia Faviana and Daniela Campani and Sara Caponi and Andrea Mambrini and Ugo Boggi and Maurizio Cantore and Michele Milella and Peters, {Godefridus J.} and Michele Reni and Elisa Giovannetti",
year = "2014",
doi = "10.2217/pgs.13.225",
language = "English",
volume = "15",
pages = "609--618",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients

AU - Maftouh, Mina

AU - Avan, Amir

AU - Funel, Niccola

AU - Paolicchi, Elisa

AU - Vasile, Enrico

AU - Pacetti, Paola

AU - Vaccaro, Vanja

AU - Faviana, Pinuccia

AU - Campani, Daniela

AU - Caponi, Sara

AU - Mambrini, Andrea

AU - Boggi, Ugo

AU - Cantore, Maurizio

AU - Milella, Michele

AU - Peters, Godefridus J.

AU - Reni, Michele

AU - Giovannetti, Elisa

PY - 2014

Y1 - 2014

N2 - Aim: EZH2 expression is a prognostic marker in radically resected pancreatic ductal adenocarcinoma (PDAC) patients. Here we investigated its role in locally advanced/metastatic patients, as well as candidate polymorphisms. Materials & methods: EZH2 expression and polymorphisms were evaluated by quantitative reverse transcription PCR in 32 laser microdissected tumors, while polymorphisms were also studied in blood samples from two additional cohorts treated with gemcitabine monotherapy (n = 93) or polychemotherapeutic regimens (n = 247). Results: EZH2 expression correlated with survival and with the rs6958683 polymorphism in the first cohort of patients, but this polymorphism was not associated with survival in our larger cohorts. Conclusion: EZH2 is a prognostic factor for locally advanced/metastatic PDACs, while candidate polymorphisms cannot predict clinical outcome. Other factors involved in EZH2 regulation, such as miR-101, should be investigated in accessible samples in order to improve the clinical management of advanced PDAC. Original submitted 31 July 2013; Revision submitted 4 November 201.

AB - Aim: EZH2 expression is a prognostic marker in radically resected pancreatic ductal adenocarcinoma (PDAC) patients. Here we investigated its role in locally advanced/metastatic patients, as well as candidate polymorphisms. Materials & methods: EZH2 expression and polymorphisms were evaluated by quantitative reverse transcription PCR in 32 laser microdissected tumors, while polymorphisms were also studied in blood samples from two additional cohorts treated with gemcitabine monotherapy (n = 93) or polychemotherapeutic regimens (n = 247). Results: EZH2 expression correlated with survival and with the rs6958683 polymorphism in the first cohort of patients, but this polymorphism was not associated with survival in our larger cohorts. Conclusion: EZH2 is a prognostic factor for locally advanced/metastatic PDACs, while candidate polymorphisms cannot predict clinical outcome. Other factors involved in EZH2 regulation, such as miR-101, should be investigated in accessible samples in order to improve the clinical management of advanced PDAC. Original submitted 31 July 2013; Revision submitted 4 November 201.

KW - EZH2

KW - gemcitabine-based chemotherapy

KW - locally advanced/metastatic

KW - outcome

KW - pancreatic ductal adenocarcinoma

KW - SNP

UR - http://www.scopus.com/inward/record.url?scp=84899803770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899803770&partnerID=8YFLogxK

U2 - 10.2217/pgs.13.225

DO - 10.2217/pgs.13.225

M3 - Article

C2 - 24798718

AN - SCOPUS:84899803770

VL - 15

SP - 609

EP - 618

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 5

ER -